|
IBRX | Immunitybio, Inc. |
|
|
IBRX | Immunitybio, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ -0.10 |
| Leverage | 199.54% |
| Market Cap | $ 4.9B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -350.7m |
| Margin | -317.66% |
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.